StemRad

StemRad was founded in 2012 by Dr. Oren Milstein and Daniel Levitt in response to the Fukushima Daiichi nuclear disaster, with the mission to develop practical, wearable personal radiation protection for first responders and critical infrastructure personnel. The company's core innovation rests on selective shielding: rather than attempting whole-body radiation protection (which would be prohibitively heavy and operationally impossible), StemRad shields stem cell-rich organs in the pelvic and abdominal regions—particularly bone marrow, the gastrointestinal tract, ovaries, and other radiosensitive tissues—allowing users to maintain full mobility and operational effectiveness while preventing acute radiation syndrome and reducing cancer risk from low-dose exposures. The technology is grounded in radiobiology: approximately 50% of the body's bone marrow is located in the hip and lower vertebrae regions; shielding these areas selectively prevents the cascade of bone marrow failure that drives acute radiation syndrome mortality and provides meaningful protection against penetrating gamma radiation without whole-body weight penalties. The company's product portfolio includes the 360 Gamma belt system for first responders and military personnel, the AstroRad suit co-developed with Lockheed Martin for space exploration, and specialized variants for nuclear industry workers and medical personnel.

StemRad has achieved demonstrable validation across civilian, defense, and space domains. The company secured a $4.5 million U.S. General Services Administration contract (on behalf of the National Guard Bureau) in December 2023 for 630 radiation protection belts and comprehensive onsite training, representing the first large-scale acquisition of its technology by the U.S. military. The contract explicitly addresses the domestic radiological incident response mission: protecting soldiers and airmen deployed to manage dirty bomb attacks, terrorist nuclear incidents, or nuclear power plant emergencies. Beyond the National Guard, the company has commercial contracts with nuclear utilities (two Florida reactors), the Negev Nuclear Research Center in Israel's Dimona facility, U.S. Capitol Police, and numerous fire departments in the U.S. and Japan. NASA validation is substantial: the AstroRad suit flew aboard the uncrewed Artemis I mission (May 2022) as a technology demonstration for protecting astronauts during deep-space missions where cosmic radiation exposure significantly exceeds LEO levels. These deployments span operational environments from urban first-response to extreme-radiation nuclear facilities to deep space, indicating genuine product-market fit rather than speculative positioning.

The company's market opportunity is substantial and growing. The global radiological threat environment has intensified in recent years: Russia's occupation of the Zaporizhzhia Nuclear Power Station (Europe's largest facility) during the Ukraine invasion, Iran and North Korea's nuclear weapons programs, and increased state actor focus on critical infrastructure targeting have elevated nuclear contingency planning across NATO and allied nations. StemRad has already donated 60 systems to Ukrainian first responders stationed near Zaporizhzhia, validating both the practical utility and the geopolitical relevance of the technology. Existing customers indicate expansion plans: Milstein stated in late 2023 that "several other US military forces are planning to acquire the tech in 2024 and 2025" and identified NATO militaries, additional U.S. combat forces, and international utilities as target customers. The addressable market encompasses military consequence management forces (all NATO nations, regional allies), nuclear facility workforces (globally 440+ reactors), first-responder networks in dense urban areas, and space exploration agencies.

Competitively, StemRad operates in a category with limited established players. Whole-body radiation shielding (e.g., traditional lead vests) is commercially available but operationally impractical for extended missions due to weight penalties exceeding 100 kg for meaningful gamma protection—incompatible with first-response, space, or prolonged military operations. StemRad's selective protection approach is differentiated: the technology is the first to achieve practical wearability without sacrificing meaningful organ protection, supported by peer-reviewed radiobiological evidence and endorsements from three Nobel laureates (including Stanford Professor Michael Levitt, who explicitly endorses StemRad's survival and cancer-risk reduction claims). The company's partnerships with NASA and Lockheed Martin on AstroRad demonstrate technical credibility with premier defense and space organizations, which serves as a strong market signal in the capital-intensive, risk-averse sectors where StemRad operates.

StemRad's financial standing reflects sustained investor confidence and scale-up readiness. The company has raised $16 million in private capital, backed by prominent investors: Jeff Vinik (former Fidelity hedge fund manager, owner of the Tampa Bay Lightning NHL team), Dr. Alex Gurevich (former JP Morgan global macro trading head), and the Patel family of Tampa Bay. The funding trajectory and investor composition suggest Series B-stage scale-up positioning with active expansion into defense and international markets. The company is headquartered in Tel Aviv with a secondary office in Tampa Bay, reflecting both Israeli origin and U.S. market focus. The team includes biology experts, nuclear physicists, industrial designers, and strategic advisors with deep credibility in nuclear policy and defense (Milstein has direct relationships with national security leadership, including personal delivery of equipment to Ukraine).

The dual-use and strategic relevance of StemRad's technology is unambiguous and operationally validated. On the civilian side, the technology directly supports critical infrastructure resilience: nuclear facility workers, first responders, and utility personnel are exposed to radiological risk as part of essential infrastructure protection. On the defense side, the technology enables military consequence management (CBRNE—chemical, biological, radiological, nuclear, explosive response), protects deployed forces in contested environments where nuclear weapons presence is a factor, and supports allied force readiness in regions of heightened nuclear tension (Eastern Europe, Indo-Pacific). The space exploration pathway is equally significant: sustained presence in lunar and cislunar space requires radiation protection solutions; NASA's selection of AstroRad for Artemis validates that the technology is mission-critical for the next generation of human spaceflight. The technology is not dual-use in the narrow sense of being "civilian-convertible"; it is inherently dual-use across the full spectrum of legitimate defense, space, and infrastructure resilience applications.